🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. Immune Globulin Intravenous (Human), 10% (IGIV, 10%)

    Takeda

    Alzheimer´s Disease

    phase 3 small molecule terminated

    1 trial

  2. Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg

    Takeda

    Alzheimer´s Disease

    phase 3 mab completed

    1 trial

  3. Immune Globulin Intravenous (Human), 10% Solution

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  4. Immune Globulin Intravenous (Human), 10% Solution

    Takeda

    Alzheimer´s Disease

    phase 3 mab terminated

    1 trial

  5. Immune Globulin Intravenous (human), 10%

    Takeda

    Multifocal Motor Neuropathy

    phase 3 mab completed

    1 trial

  6. Imnovid 1 mg hard capsules, CC-92480, CC-92480, Dexamethason-ratiopharm® 4 mg Tabletten, Imnovid 4 mg hard capsules, Dexamethason CF 20 mg/ml, injectievloeistof, CC-92480, Dexamethason 4 mg JENAPHARM®, Imnovid 2 mg hard capsules, DEXAMETHASONE, Dexamethason 4 mg GALEN®, CC-92480, Imnovid 3 mg hard capsules, CC-92480, CC-92480, VELCADE 1 mg powder for solution for injection

    Celgene Europe Limited

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 3 small molecule active

    1 trial

  7. Imnovid 1 mg hard capsules, Kyprolis 60 mg powder for solution for infusion, Privigen 100 mg/ml solution for infusion, Pomalidomide, Pomalidomide, Dexamethason 8 mg GALEN® Tabletten, VELCADE 3.5 mg powder for solution for injection, Imnovid 3 mg hard capsules, Dexamethasone Tablets BP 2.0mg, Privigen 100 mg/ml solution for infusion, teclistamab, Pomalidomide, Dexamethason 4 mg JENAPHARM®, Fortecortin® 2 mg Tabletten, teclistamab, Pomalidomide, Imnovid 4 mg hard capsules, Privigen 100 mg/ml solution for infu

    Janssen-Cilag International N.V.

    Relapsed/refractory multiple myeloma

    phase 3 small molecule active

    1 trial

  8. Imnovid 3 mg hard capsules, DARZALEX 20 mg/mL concentrate for solution for infusion, Bortezomib Fresenius Kabi 3.5 mg powder for solution for injection, DARZALEX 20 mg/mL concentrate for solution for infusion, Kyprolis 30 mg powder for solution for infusion, Kyprolis 60 mg powder for solution for infusion, Imnovid 1 mg hard capsules, Neofordex 40 mg tablets, Imnovid 4 mg hard capsules, Imnovid 2 mg hard capsules, Kyprolis 10 mg powder for solution for infusion, Anitocabtagene autoleucel, Bortezomib Freseniu

    Lacuna Pharma Pty Ltd

    Relapsed/refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy and have been exposed to both an immunomodulatory drug and an anti-CD38 monoclonal antibody

    phase 3 small molecule active

    1 trial

  9. Imnovid 3 mg hard capsules, DEXAMETHASONE , Venetoclax, Imnovid 1 mg hard capsules, Imnovid 4 mg hard capsules, Imnovid 2 mg hard capsules

    AbbVie Deutschland GmbH & Co. KG

    R/R Multiple Myeloma

    phase 3 small molecule active

    1 trial

  10. Imnovid 3 mg hard capsules, Imnovid 4 mg hard capsules, Dexamethasone Tablets BP 2.0mg, Dexamethason 8 mg GALEN® Tabletten, Imnovid 2 mg hard capsules, Dexamethason 8 mg JENAPHARM®, Dexamethasone 2mg Tablets, Imnovid 1 mg hard capsules, VELCADE 3.5 mg powder for solution for injection

    GlaxoSmithKline

    Relapsed/Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  11. Imnovid 3 mg hard capsules, Isatuximab, Dexamethason 4 mg JENAPHARM®, JAMP Pomalidomide, JAMP Pomalidomide, Isatuximab, Imnovid 4 mg hard capsules, JAMP Pomalidomide, MONTELUKAST , Pomalidomide Adalvo 4 mg hard capsules, JAMP Pomalidomide, Imnovid 2 mg hard capsules, Pomalidomide Adalvo 2 mg hard capsules, Imnovid 1 mg hard capsules, Pomalidomide Adalvo 3 mg hard capsules, DEXAMETHASONE, Imnovid 1 mg hard capsules, Isatuximab, Imnovid 2 mg hard capsules, Pomalidomide Adalvo 1 mg hard capsules, Dexamethason

    Sanofi-aventis Healthcare Pty Ltd

    Cancer - Plasma cell myeloma recurrent

    phase 3 small molecule active

    1 trial

  12. Inactivated COVID-19 Vaccine

    Sinovac Research and Development Co.,

    COVID-19

    phase 3 mab completed

    4 trials

  13. Indacaterol 150 μg

    Novartis Pharmaceuticals

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule completed

    1 trial

  14. Indacaterol 150 μg

    Novartis Pharmaceuticals

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule completed

    2 trials

  15. Influenza A (H5N1) Virus monovalent vaccine

    GlaxoSmithKline

    Influenza

    phase 3 mab completed

    1 trial

  16. Influenza vaccine GSK1562902A Formulation 1

    GlaxoSmithKline

    Influenza

    phase 3 mab completed

    1 trial

  17. Influenza vaccine GSK2321138A

    GlaxoSmithKline

    Influenza

    phase 3 mab completed

    1 trial

  18. Influsplit Tetra 2024/2025 Injektionssuspension in Fertigspritze Influenza-Spaltimpfstoff (inaktiviert)

    Moderna Biotech Spain

    Influenza

    phase 3 small molecule active

    1 trial

  19. Instant MSC Product accompanying Autologous Chondron Transplantation (IMPACT)

    Disc Medicine

    Symptomatic articular cartilage lesion of the knee (femoral condyles or trochlea)

    phase 3 small molecule active

    1 trial

  20. Insulatard 100 international units/ml suspension for injection in vial., Natriumchloride 0,9% oplossing voor injectie

    Disc Medicine

    Delirium

    phase 3 small molecule active

    1 trial

  21. Insulin glargine/Lixisenatide (HOE901/AVE0010)

    Sanofi Pasteur

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  22. Intrarosa 6.5 mg pessary

    Istituto Gentili S.r.l.

    Postmenopausal women with previous breast cancer or currently under anti-oesterogenic therapy (aromatase inhibitor +/- LHRH analogue) presenting vulvar, vaginal or urinary bothersome symptoms (genitourinary syndrome).

    phase 3 small molecule active

    1 trial

  23. Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  24. Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)

    Regeneron UK Limited

    Branch Retinal Vein Occlusion

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources